vimarsana.com

Page 3 - எலும்பியல் மருத்துவ பரிசோதனை ஹோல்டிங்ஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Anixa Biosciences (ANIX) Receives a Rating Update from a Top Analyst

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) today and set a price target of $11.00. The company’s shares closed last Monday at $4.06. According to TipRanks.com, Chen is a top 100 analyst with an average return of 61.9% and a 50.9% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anixa Biosciences with a $11.00 average price target. Based on Anixa Biosciences’ latest earnings release for the quarter ending January 31, the company reported a quarterly revenue of $512.5K and GAAP net loss of $2.21 million. In comparison, last year the company had a GAAP net loss of $2.59 million.

REPLACING: Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results

REPLACING: Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results

Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Goldman Sachs Predicts Over 50% Rally for These 2 Stocks

Stocks started this year with heft gains, edged back last week, and now are rising again. The big tech giants led the moves, with volatility in Apple and Amazon leading the NASDAQ on its gyrations. The strategy team at investment bank Goldman Sachs have taken notice of the market shakeups, and are working out what it means for investors. According to macro strategist Gurpreet Gill, watching bond yields and stock values closely, “The rise in global yields is a reflection of improved growth prospects given encouraging vaccine progress and in the US forthcoming sizeable fiscal stimulus. [It] also signals higher inflation expectations and in turn pulled forward expectations for the timing of monetary policy normalization.” Monetary policy may be key to calming investor worries – and on that score, Federal Reserve Chair Jerome Powell’s testimony to Congress is seen as positive. In his comments to lawmakers, the head of the central bank indicated that the Fed has

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) - The Week Ahead In Biotech: J&J Vaccine Adcom Meeting, Sarepta FDA Decision And Plenty Of Earnings

Concert Pharmaceuticals Inc (NASDAQ: CNCE) (before the market open) Kala Pharmaceuticals Inc (NASDAQ: KALA) (before the market open) Jounce Therapeutics Inc (NASDAQ: JNCE) (before the market open) Intellia Therapeutics Inc (NASDAQ: NTLA) (before the market open) Moderna Inc (NASDAQ: MRNA) (before the market open) Radius Health Inc (NASDAQ: RDUS) (before the market open) Insmed Incorporated (NASDAQ: INSM) (before the market open) Intercept Pharmaceuticals Inc (NASDAQ: ICPT) (before the market open) Editas Medicine Inc (NASDAQ: EDIT) (before the market open) Mediwound Ltd (NASDAQ: MDWD) (before the market open) Novocure Ltd (NASDAQ: NVCR) (before the market open) Glaukos Corp (NYSE: GKOS) (before the market open)

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.